PolyPid Announces Presentation at the 13th European and Global CLINAM Summit for Nanomedicine

Rhea-AI Summary

PolyPid Ltd. (Nasdaq: PYPD) announced the presentation of clinical data at the 13th European and Global CLINAM Summit for Nanomedicine, focusing on D-PLEX₁₀₀. The study demonstrated D-PLEX₁₀₀ as an effective surgical site infection prevention agent in colorectal surgery patients, limiting antimicrobial resistance (AMR) without increasing postoperative colonization by multi-drug resistant organisms. This emphasizes the potential of PolyPid's proprietary PLEX technology in enhancing surgical outcomes. The presentation will be accessible on their website after the summit.

Positive

• D-PLEX100 demonstrated effectiveness in preventing surgical site infections.
• No increase in antimicrobial resistance (AMR) observed in trial.
• Presentation at a significant summit showcases company innovation.

Negative

• None.

Presentation evaluates the effect of D-PLEX₁₀₀ in limiting occurrence of antimicrobial resistance (AMR) in colorectal surgery patients

PETACH TIKVA, Israel, April 25, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, announced today that the Company will present clinical data at the 13th European and Global CLINAM Summit for Nanomedicine, being held virtually on May 2–4, 2022. The focus of this year’s summit is From Hope to Product – The Brilliant Prospect in Nanomedicine and Related Fields.

Dr. Noam Emanuel, Chief Scientific Officer of PolyPid, will present the abstract, ‘From Bench to Bedside: D-PLEX₁₀₀ Limits AMR Occurrence in Randomized Double-Blind Phase 2 Trial in Colorectal Surgery Patients,’ demonstrating D-PLEX₁₀₀ as a safe and effective surgical site infection prevention agent without affecting the incidence of postoperative colonization by multi drug resistant organisms. Dr. Emanuel’s presentation will be available on https://www.polypid.com/ following the summit.

About PolyPid

PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients, enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX₁₀₀ is in Phase 3 clinical trials for the prevention of soft tissue abdominal and sternal bone surgical site infections. In addition, the company is currently in preclinical stages to test the efficacy of OncoPLEX for treatment of solid tumors, beginning with glioblastoma. For additional company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn.

Corporate Contact:

PolyPid, Ltd.
Dikla Czaczkes Akselbrad
EVP & CFO
Tel: +972-747195700

Investor Contact:
Bob Yedid
LifeSci Advisors
646-597-6989
Bob@LifeSciAdvisors.com

Media Contact:
Nechama Feuerstein
FINN Partners
551-444-0784
Nechama.Feuerstein@finnpartners.com

FAQ

What results were presented about D-PLEX100 at the CLINAM Summit?

The results showed that D-PLEX100 effectively prevents surgical site infections without increasing antimicrobial resistance in colorectal surgery patients.

When is the presentation about D-PLEX100 available?

The presentation will be available on PolyPid's website after the CLINAM Summit, which runs from May 2-4, 2022.

What is PolyPid's lead product candidate?

PolyPid's lead product candidate is D-PLEX100, which is in Phase 3 trials for preventing surgical site infections.

What technology does PolyPid use for drug delivery?

PolyPid uses its proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology for drug delivery.

What is the focus of the CLINAM Summit where PolyPid presented?

The CLINAM Summit focuses on advancements in nanomedicine and related fields under the theme 'From Hope to Product'.